LivingGLP1
Study S002634

Safety and Outcomes of Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A Case Series

ClinicalTrials.gov record

Registration

Registration
NCT07224880
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
9
Start
2025-10-14
Primary completion
2026-08-21
Lead sponsor
Cytrellis Biosystems, Inc.
Conditions
glp1 Agonist; Gene Expression; Skin Laxity
Interventions
DEVICE:ellacor
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Safety and Outcomes [study time frame]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.